Billich Andreas
Novartis Research Institute, PO Box 80, Brunner Strasse 59, 1235 Vienna, Austria.
Curr Opin Investig Drugs. 2003 Feb;4(2):210-3.
MedImmune, in collaboration with GlaxoSmithKline, is developing a vaccine consisting of self-assembling, virus-like particles for the prevention of human papillomavirus (HPV) infection of the genital tract and associated cervical cancer. The vaccine candidates include the prototype vaccine, MEDI-501 (a vaccine directed against HPV-11), MEDI-503 (directed against HPV-16) and MEDI-504 (directed against HPV-18). Following phase I studies, the HPV-16 and HPV-18 components were combined into a multivalent vaccine for subsequent trials; this vaccine is known as MEDI-517. Phase II trials of MEDI-517 were initiated by January 2000 and are currently ongoing.
MedImmune公司与葛兰素史克公司合作，正在研发一种由自组装病毒样颗粒组成的疫苗，用于预防生殖道人乳头瘤病毒（HPV）感染及相关宫颈癌。候选疫苗包括原型疫苗MEDI - 501（一种针对HPV - 11的疫苗）、MEDI - 503（针对HPV - 16）和MEDI - 504（针对HPV - 18）。在I期研究之后，HPV - 16和HPV - 18成分被组合成一种多价疫苗用于后续试验；这种疫苗被称为MEDI - 517。MEDI - 517的II期试验于2000年1月启动，目前正在进行中。
